ArticleGynecologic oncology reports2026
Disparities in not recommending chemotherapy for individuals with newly diagnosed advanced endometrial cancer due to "patient risk factors".
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objectives: We sought to identify patient sociodemographic characteristics associated with not recommending chemotherapy due to "patient risk factors" for individuals diagnosed with advanced-stage endometrial cancer. Methods: We conducted a retrospective analysis of individuals newly diagnosed with stage III or IV endometrial cancer between 2004-2021 utilizing the National Cancer Database (NCDB). The primary outcome was indication that "chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age […])" compared to chemotherapy recommended, regardless of administration. A logistic regression model examined associations between patient sociodemographic characteristics (age, race, ethnicity, education, type of insurance, urban/rural residence) and not recommending chemotherapy due to patient risk factors, adjusting for clinical factors including Charlson-Deyo comorbidity index scores, stage, histology, grade, and facility type. Results: Among the 96,497 individuals included in the analysis, chemotherapy was not recommended for 2,030 (2.1%) due to "patient risk factors." Increasing age, Black race, living in a zip code with lower rates of high school completion, and having no insurance or government insurance were independently associated with chemotherapy not being recommended after adjusting for clinical variables. Sensitivity analyses excluding subgroups more likely to have clinical contraindications, including those who did not have surgery, had a Charlson-Deyo comorbidity index score > 0, or died within 30 days of surgery found similar results. Conclusions: Despite National Comprehensive Cancer Network guidelines recommending chemotherapy for frontline treatment of advanced-stage endometrial cancer, disparities in recommendations for chemotherapy were observed by sociodemographic factors including race, age, education, and insurance status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.